TNXP Tonix Pharmaceuticals Holding Corp.

0.46
0  -0%
Previous Close 0.46
Open 0.46
Price To Book 0.55
Market Cap 7,035,847
Shares 15,362,112
Volume 35,919
Short Ratio
Av. Daily Volume 470,974

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 data September 6, 2016 did not meet primary endpoint - program discontinued. However company noted April 4, 2019 intention to initiate a Phase 3 trial.
TNX-102 SL
Fibromyalgia
Phase 3 data due 1H 2020.
Tonmya
Post-traumatic stress disorder (PTSD)
In-licensed - noted May 23, 2019.
TNX-1300 (RBP-8000)
Cocaine intoxication
Phase 1 pharmacokinetic study data due 2H 2019.
TNX-601
PK trial

Latest News

  1. Tonix Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights
  2. Tonix Pharmaceuticals Announces Director Stepping Down
  3. Tonix Pharmaceuticals Announces Issuance of U.S. Patent for the Composition and Formulation of TNX-102 SL
  4. Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock
  5. Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  6. TNXP: Enrollment Continues for Phase 3 Trial of TNX-102 SL in PTSD…
  7. Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
  8. Tonix Pharmaceuticals to Present at BIO 2019 International Convention
  9. How Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Affect Your Portfolio Volatility?
  10. Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication
  11. Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology
  12. Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
  13. Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA
  14. Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)
  15. Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
  16. TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway…
  17. Four Healthcare Stocks Heating Up on Thursday
  18. What's Driving The Rally In Nanocap Biotech Tonix Pharma?